In 2014, the Liberian Minister of Health had required the U.S. Secretary of Health and Human Services to for a partnership between Research on Ebola Virus in Liberia and the U.S. Liberia clinical research. The collaboration now seems to be reaching a concrete result as the results from a large and randomized clinical trial in Liberia has shown that two candidate Ebola vaccines can impart immunity of at least a year on the subject. The study was done on 1,500 adults across West Africa between February 2, 2015 and April 30, 2015, wherein the outbreak of Ebola has been most prevalent.
More Ebola Outbreaks are Inevitable
The National Institutes of Health (NIH) dedicated its branch known as the National Institute of Allery and Infectious Diseases (NIAID) for this study, which involved researchers and scientists from United States and Liberia. As per the Director of NIAID, Anthony S. Fauci, these clinical trials have produced valuable details which can be highly beneficial for the continuous development of two Ebola vaccine candidates. He asserts that the Ebola outbreaks are inevitable in the future, and these candidates can formulate a safe and effective vaccine that can be highly useful during the troubled times.
One of the vaccine candidate includes cAd3-EBOZ, which was developed by GlaxoSmithKline in association with NIAID’s Vaccine Research Center, whereas the other candidate includes rVSV-ZEBOV, which is licensed by Merck Sharp & Dohme Corp, a subsidy of Merck & Co., Inc., and was engineered by a group of scientists from the Public Health Agency of Canada.